<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Akiyama H</submitter><funding>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</funding><funding>Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Cancer Institute</funding><funding>Daiichi Sankyo Company</funding><funding>Uehara Memorial Foundation</funding><funding>NCI NIH HHS</funding><funding>Cancer Prevention and Research Institute of Texas</funding><journal>Blood cancer journal</journal><pagination>76</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12022017</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.</pubmed_title><pmcid>PMC12022017</pmcid><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>NA</funding_grant_id><funding_grant_id>1 R50 CA243707-01A1</funding_grant_id><funding_grant_id>RP121010</funding_grant_id><pubmed_authors>Bedoy AD</pubmed_authors><pubmed_authors>Basyal M</pubmed_authors><pubmed_authors>Muftuoglu M</pubmed_authors><pubmed_authors>Andreeff M</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Ma W</pubmed_authors><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Rampal RK</pubmed_authors><pubmed_authors>Chang KH</pubmed_authors><pubmed_authors>Akiyama H</pubmed_authors><pubmed_authors>Honma D</pubmed_authors><pubmed_authors>Oluwole OO</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Daver NG</pubmed_authors><pubmed_authors>Tsutsumi S</pubmed_authors><pubmed_authors>Bixby DL</pubmed_authors><pubmed_authors>Hirschi Z</pubmed_authors><pubmed_authors>Nishida Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2025-07-10T03:08:55.703Z</modification><creation>2025-07-10T03:08:55.703Z</creation></dates><accession>S-EPMC12022017</accession><cross_references><pubmed>40274779</pubmed><doi>10.1038/s41408-025-01266-0</doi></cross_references></HashMap>